Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum
Clinical Infectious Diseases · 26.09.2024 · 79 (3) · 787-794
DOI: 10.1093/cid/ciae321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 23.07.2024. Verfasst von Per Ljungman und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Cen…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Antiviral Agents, Cytomegalovirus, Transplant Recipients. Die Arbeit wurde bisher 206-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Forum, AiCuris, AlloVir.
Abstract (Originalsprache)
Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most recently published in 2017. Since then, there have been major developments, including registration of new antiviral agents. Therefore, the Transplant Associated Virus Infections Forum, which consists of scientists, clinicians, regulators, and industry representatives, has produced an updated version of these definitions that incorporates recent knowledge with the aim of supporting clinical research and drug development. This also includes an update regarding the definition of resistant and refractory CMV infections previously published in 2019. As the field evolves, the need for updates of these definitions is clear, and collaborative efforts among clinicians, scientists, regulators, and industry representatives can provide a platform for this work.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Stockholm, Sweden.
- Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Laboratoire de Bactériologie-Virologie-Hygiène, French National Reference Center for Herpesviruses, CHU Limoges, Limoges, France.
- Division of Infectious Diseases, Johns Hopkins, Baltimore, Maryland, USA.
- Merck & Co, Inc., Rahway, New Jersey, USA.
ORCID-Profile: Per Ljungman, Raymund R Razonable
Förderung
- Forum
- AiCuris
- AlloVir
- Evrys Bio
- HHV-6 Foundation
- Merck
- Takeda
- Symbio
Zitieren
APA
Ljungman, P., Chemaly, R. F., Khawaya, F., Alain, S., Avery, R., Badshah, C., Boeckh, M., Fournier, M., Hodowanec, A., Komatsu, T., Limaye, A. P., Manuel, O., Natori, Y., Navarro, D., Pikis, A., Razonable, R. R., Westman, G., Miller, V., Griffiths, P. D., …, & CMV Definitions Working Group of the Transplant Associated Virus Infections Forum (2024). Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clinical Infectious Diseases, 79(3), 787-794. https://doi.org/10.1093/cid/ciae321
Vancouver
Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, et al. Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clinical Infectious Diseases. 2024;79(3):787-794. doi:10.1093/cid/ciae321
BibTeX
@article{Ljungman2024,
author = {Ljungman, Per and Chemaly, Roy F and Khawaya, Fareed and Alain, Sophie and Avery, Robin and Badshah, Cyrus and Boeckh, Michael and Fournier, Martha and Hodowanec, Aimee and Komatsu, Takashi and Limaye, Ajit P and Manuel, Oriol and Natori, Yoichiro and Navarro, David and Pikis, Andreas and Razonable, Raymund R and Westman, Gabriel and Miller, Veronica and Griffiths, Paul D and Kotton, Camille N and CMV Definitions Working Group of the Transplant Associated Virus Infections Forum, CMV Definitions Working Group of the Transplant Associated Virus Infections Forum},
title = {Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {79},
number = {3},
pages = {787--794},
doi = {10.1093/cid/ciae321}
}
EUVIMED